Cannabis use during pregnancy: Pharmacokinetics and effects on child development

Pharmacology and Therapeutics

Volumn 182, Issue , 2018, Pages 133-151

  Grant, Kimberly S ^a   Petroff, Rebekah ^a   Isoherranen, Nina ^a   Stella, Nephi ^b   Burbacher, Thomas M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Child development; Exposure; Pharmacokinetics; Pregnancy

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; PHYTOCANNABINOID; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; DRONABINOL;

ADAPTIVE BEHAVIOR; ADULT; BEHAVIOR; BODY GROWTH; BRAIN DEVELOPMENT; CANNABIS USE; CHILD DEVELOPMENT; COGNITION; DRUG EFFECT; EMOTIONALITY; HUMAN; MATURATION; NONHUMAN; PHARMACOKINETICS; PHYSICAL ACTIVITY; PLACENTA; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL WELL-BEING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; BRAIN; CHEMICALLY INDUCED; FEMALE; GROWTH, DEVELOPMENT AND AGING; PRENATAL EXPOSURE;

ANIMALS; BRAIN; COGNITION; DRONABINOL; FEMALE; HUMANS; MARIJUANA USE; MODELS, NEUROLOGICAL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 85028951675     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.08.014     Document Type: Review

References (203)

1. Abel, E.L., Effects of ∆ 9-THC on pregnancy and offspring in rats. Neurobehavioral Toxicology and Teratology 6:1 (1984), 29–32.
2. Abood, M., Sorensen, R., Stella, N., (eds.) endoCANNABINOIDS: Actions at non-CB1/CB2 cannabinoid receptors, 24th ed., 2012, Springer Science & Business Media.
3. Abrams, R.M., Cook, C.E., Davis, K.H., Niederreither, K., Jaeger, M.J., Szeto, H.H., Plasma delta-9-tetrahydrocannabinol in pregnant sheep and fetus after inhalation of smoke from a marijuana cigarette. Alcohol and Drug Research 6:5 (1984), 361–369.
4. Aguado, T., Monory, K., Palazuelos, J., Stella, N., Cravatt, B., Lutz, B., Galve-Roperh, I., The endocannabinoid system drives neural progenitor proliferation. The FASEB Journal 19:12 (2005), 1704–1706, 10.1096/fj.05-3995fje.
5. Aguado, T., Palazuelos, J., Monory, K., Stella, N., Cravatt, B., Lutz, B., Galve-Roperh, I., The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. The Journal of Neuroscience 26:5 (2006), 1551–1561, 10.1523/JNEUROSCI.3101-05.2006.
6. Ahmed, A.I.A., Van Den Elsen, G.A.H., Colbers, A., Kramers, C., Burger, D.M., van der Marck, M.A., Olde Rikkert, M.G.M., Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology 232:14 (2015), 2587–2595, 10.1007/s00213-015-3889-y.
7. Alpár, A., Tortoriello, G., Calvigioni, D., Niphakis, M.J., Milenkovic, I., Bakker, J., Harkany, T., Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. Nature Communications, 5, 2014, 4421, 10.1038/ncomms5421.
8. American Chemical Society, Legalizing marijuana and the new science of weed [press release]. Retrieved May 3, 2017, from https://www.acs.org/content/acs/en/pressroom/newsreleases/2015/march/legalizing-marijuana-and-the-new-science-of-weedvideo.html?_ga=1.115036224.695999133.1470076540, 2015.
9. Asch, R.H., Smith, C.G., Effects of delta 9-THC, the principal psychoactive component of marijuana, during pregnancy in the rhesus monkey. The Journal of Reproductive Medicine 31:12 (1986), 1071–1081.
10. Astley, S.J., Little, R.E., Maternal marijuana use during lactation and infant development at one year. Neurotoxicology and Teratology 12:2 (1990), 161–168, 10.1016/0892-0362(90)90129-Z.
11. Atwood, B.K., Huffman, J., Straiker, A., MacKie, K., JWH018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. British Journal of Pharmacology 160:3 (2010), 585–593, 10.1111/j.1476-5381.2009.00582.x.
12. Azofeifa, A., Mattson, M.E., Schauer, G., McAfee, T., Grant, A., Lyerla, R., National estimates of marijuana use and related indicators - National Survey on Drug Use and Health, United States, 2002–2014. Morbidity and Mortality Weekly Report. Surveillance Summaries 65:11 (2016), 1–28, 10.15585/mmwr.ss6511a1.
13. Bada, H.S., Reynolds, E.W., Hansen, W.F., Marijuana use, adolescent pregnancy, and alteration in newborn behavior: How complex can it get?. The Journal of Pediatrics 149:6 (2006), 742–745, 10.1016/j.jpeds.2006.10.049.
14. Bailey, J.R., Cunny, H.C., Paule, M.G., Slikker, W., Fetal disposition of Δ9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicology and Applied Pharmacology 90:2 (1987), 315–321, 10.1016/0041-008X(87)90338-3.
15. Bellinger, D.C., Matthews-Bellinger, J.A., Kordas, K., A developmental perspective on early-life exposure to neurotoxicants. Environment International 94 (2016), 103–112, 10.1016/j.envint.2016.05.014.
16. Benevenuto, S.G., Domenico, M.D., Martins, M.A.G., Costa, N.S., de Souza, A.R.L., Costa, J.L., Veras, M.M., Recreational use of marijuana during pregnancy and negative gestational and fetal outcomes: An experimental study in mice. Toxicology 1:376 (2017), 94–101, 10.1016/j.tox.2016.05.020.
17. Berghuis, P., Rajnicek, A.M., Morozov, Y.M., Ross, R.A., Mulder, J., Urbán, G.M., Harkany, T., Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 316:5828 (2007), 1212–1216, 10.1126/science.1137406.
18. Blackard, C., Tennes, K., Human placental transfer of cannabinoids. New England Journal of Medicine, 311, 1984, 797.
19. Bland, T.M., Haining, R.L., Tracy, T.S., Callery, P.S., CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochemical Pharmacology 70:7 (2005), 1096–1103, 10.1126/science.1137406.
20. 9-tetrahydrocannabinol on the dopamine system. Nature 539:7629 (2016), 369–377, 10.1038/nature20153 (Review. PMID: 27853201).
21. Borgen, L.A., Davis, W.M., Pace, H.B., Effects of prenatal ∆ 9-tetrahydrocannabinol on the development of rat offspring. Pharmacology Biochemistry and Behavior 1 (1973), 203–206.
22. Bornheim, L.M., Lasker, J.M., Raucy, J.L., Human hepatic microsomal metabolism of ∆ 1-tetrahydrocannabinol. Drug Metabolism and Disposition 20:2 (1992), 241–246.
23. Boskovic, R., Klein, J., Woodland, C., Karaskov, T., Koren, G., The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: A twin study. Canadian Journal of Physiology and Pharmacology 79:11 (2001), 942–945, 10.1139/y01-080.
24. Brake, S.C., Hutchings, D.E., Morgan, B., Lasalle, E., Shi, T., Delta-9-tetrahydrocannabinol during pregnancy in the rat: II. Effects on ontogeny of locomotor activity and nipple attachment in the offspring. Neurotoxicology and Teratology 9:1 (1987), 45–49, 10.1016/0892-0362(87)90069-9.
25. Brents, L.K., Marijuana, the endocannabinoid system and the female reproductive system. Yale J. Biol. Med. 89:2 (2016), 175–191 (eCollection 2016 Jun. Review. PMID: 27354844).
26. Brown, Q.L., Sarvet, A.L., Shmulewitz, D., Martins, S.S., Wall, M.M., Hasin, D.S., Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. JAMA 72:12 (2016), 1235–1242, 10.1001/jama.2016.17383.
27. Buser, G.L., Gerona, R.R., Horowitz, B.Z., Vian, K.P., Troxell, M.L., Hendrickson, R.G., Leman, R.F., Acute kidney injury associated with smoking synthetic cannabinoid. Clinical Toxicology 52:7 (2014), 664–673, 10.3109/15563650.2014.932365.
28. Calvigioni, D., Hurd, Y.L., Harkany, T., Keimpema, E., Neuronal substrates and functional consequences of prenatal cannabis exposure. European Child & Adolescent Psychiatry 23:10 (2014), 931–941, 10.1007/s00787-014-0550-y.
29. Campolongo, P., Trezza, V., Cassano, T., Gaetani, S., Morgese, M.G., Ubaldi, M., Cuomo, V., Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addiction Biology 12:3–4 (2007), 485–495, 10.1111/j.1369-1600.2007.00074.x.
30. Campolongo, P., Trezza, V., Ratano, P., Palmery, M., Cuomo, V., Developmental consequences of perinatal cannabis exposure: Behavioral and neuroendocrine effects in adult rodents. Psychopharmacology 214:1 (2011), 5–15, 10.1007/s00213-010-1892-x.
31. Castelli, M.P., Paola Piras, A., D'Agostino, A., Pibiri, F., Perra, S., Gessa, G.L., Pistis, M., Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. European Journal of Pharmacology 573:1–3 (2007), 11–19, 10.1016/j.ejphar.2007.06.047.
32. Castillo, P.E., Younts, T.J., Chávez, A.E., Hashimotodani, Y., Endocannabinoid signaling and synaptic function. Neuron 76:1 (2012), 70–81, 10.1016/j.neuron.2012.09.020.
33. Center for Behavioral Health Statistics and Quality, Results from the 2015 National Survey on Drug Use and Health: Detailed tables. Rockville, Maryland. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.pdf, 2016.
34. Chambers, R.A., Taylor, J.R., Potenza, M.N., Developmental neurocircuitry of motivation in adolescence: A critical period of addiction vulnerability. American Journal of Psychiatry 160:6 (2003), 1041–1052, 10.1176/appi.ajp.160.6.1041.
35. Christensen, H.D., Freudenthal, R.I., Gidley, J.T., Rosenfeld, R., Boegli, G., Testino, L., Wall, M.E., Activity of ∆ 8- and ∆ 9-tetrahydrocannabinol and related compounds in the mouse. Science 172:3979 (1971), 165–167.
36. Conner, S.N., Carter, E.B., Tuuli, M.G., Macones, G.A., Cahill, A.G., Maternal marijuana use and neonatal morbidity. American Journal of Obstetrics and Gynecology 213:3 (2015), 422.e1–422.e4, 10.1016/j.ajog.2015.05.050.
37. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., Lichtman, A.H., Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of the National Academy of Sciences 98:16 (2001), 9371–9376, 10.1073/pnas.161191698.
38. Crews, F., He, J., Hodge, C., Adolescent cortical development: A critical period of vulnerability for addiction. Pharmacology Biochemistry and Behavior 86:2 (2007), 189–199, 10.1016/j.pbb.2006.12.001.
39. Cristino, L., Di Marzo, V., Fetal cannabinoid receptors and the “dis-joint-ed” brain. The EMBO Journal 33:7 (2014), 665–667, 10.1002/embj.201488086.
40. Dahl, R.E., Scher, M.S., Williamson, D.E., Robles, N., Day, N.L., A longitudinal study of prenatal marijuana use: Effects on sleep and arousal at age 3 years. Archives of Pediatrics & Adolescent Medicine, 149(2), 1995, 145, 10.1001/archpedi.1995.02170140027004.
41. Day, N.L., Leech, S.L., Goldschmidt, L., The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. Neurotoxicology and Teratology 33:1 (2011), 129–136, 10.1016/j.ntt.2010.07.006.
42. Day, N.L., Richardson, G.A., Geva, D., Robles, N., Alcohol, marijuana, and tobacco: Effects of prenatal exposure on offspring growth and morphology at age six. Alcoholism: Clinical and Experimental Research 18:4 (1994), 786–794, 10.1111/j.1530-0277.1994.tb00041.x.
43. De Chiara, V., Angelucci, F., Rossi, S., Musella, A., Cavasinni, F., Cantarella, C., Centonze, D., Brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum. Journal of Neuroscience 30:24 (2010), 8127–8137, 10.1523/JNEUROSCI.1683-10.2010.
44. De March, Z., Zuccato, C., Giampia, C., Patassini, S., Bari, M., Gasperi, V., Fusco, F.R., Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions. Neuroscience 152:3 (2008), 734–740, 10.1016/j.neuroscience.2007.11.044.
45. de Salas-Quiroga, A., Díaz-Alonso, J., García-Rincón, D., Remmers, F., Vega, D., Gómez-Cañas, M., Galve-Roperh, I., Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB 1 receptors on developing cortical neurons. Proceedings of the National Academy of Sciences of the United States of America 112:44 (2015), 1–6, 10.1073/pnas.1514962112.
46. Devane, W.A., Dysarz, F.A. III, Johnson, M.R., Melvin, L.S., Howlett, A.C., Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34:5 (1988), 605–613.
47. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C., Piomelli, D., Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:6507 (1994), 686–691, 10.1038/372686a0.
48. Diamond, A., Lee, K., Interventions shown to aid executive function development in children 4 to 12 years old. Science 333:6045 (2011), 959–964, 10.1126/science.1204529.
49. Díaz-Alonso, J., Aguado, T., Wu, C.-S., Palazuelos, J., Hofmann, C., Garcez, P., Galve-Roperh, I., The CB(1) cannabinoid receptor drives corticospinal motor neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis. The Journal of Neuroscience 32:47 (2012), 16651–16665, 10.1523/JNEUROSCI.0681-12.2012.
50. Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L., Piomelli, D., Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of the United States of America 99:16 (2002), 10819–10824, 10.1073/pnas.152334899.
51. Dinh, T.P., Kathuria, S., Piomelli, D., RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Molecular Pharmacology 66:5 (2004), 1260–1264, 10.1124/mol.104.002071.
52. Dinis-Oliveira, R.J., Metabolomics of ∆ 9-tetrahydrocannabinol: Implications in toxicity. Drug Metabolism Reviews 2532:1 (2016), 80–87, 10.3109/03602532.2015.1137307.
53. du Plessis, S.S., Agarwal, A., Syriac, A., Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. J. Assist. Reprod. Genet. 32:11 (2015), 1575–1588, 10.1007/s10815-015-0553-8 (Epub 2015 Aug 16. Review. PMID: 26277482).
54. El Marroun, H., Hudziak, J.J., Tiemeier, H., Creemers, H., Steegers, E.A., Jaddoe, V.W., Huizink, A.C., Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug and Alcohol Dependence 118:2–3 (2011), 470–474, 10.1016/j.drugalcdep.2011.03.004.
55. El Marroun, H., Tiemeier, H., Franken, I.H.A., Jaddoe, V.W.V., Van Der Lugt, A., Verhulst, F.C., White, T., Prenatal cannabis and tobacco exposure in relation to brain morphology: A prospective neuroimaging study in young children. Biological Psychiatry 79:12 (2015), 1–9, 10.1016/j.biopsych.2015.08.024.
56. El Marroun, H., Tiemeier, H., Steegers, E.A., Jaddoe, V.W., Hofman, A., Verhulst, F.C., Huizink, A.C., Intrauterine cannabis exposure affects fetal growth trajectories: The Generation R Study. Journal of the American Academy of Child and Adolescent Psychiatry 48:12 (2009), 1173–1181, 10.1016/S1090-798X(10)79394-2.
57. ElSohly, M.A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., Church, J.C., Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. Biological Psychiatry 79:7 (2016), 613–619, 10.1016/j.biopsych.2016.01.004.
58. Falcon, M., Pichini, S., Joya, J., Pujadas, M., Sanchez, A., Vall, O., Pellegrini, M., Maternal hair testing for the assessment of fetal exposure to drug of abuse during early pregnancy: Comparison with testing in placental and fetal remains. Forensic Science International 218:1–3 (2012), 92–96, 10.1016/j.forsciint.2011.10.022.
59. Fergusson, D.M., Horwood, L.J., Northstone, K., Maternal use of cannabis and pregnancy outcome. BJOG: An International Journal of Obstetrics and Gynaecology 109:1 (2002), 21–27.
60. Frank, D.A., Kuranz, S., Appugliese, D., Cabral, H., Chen, C., Crooks, D., Rose-Jacobs, R., Problematic substance use in urban adolescents: Role of intrauterine exposures to cocaine and marijuana and post-natal environment. Drug and Alcohol Dependence 142 (2014), 181–190, 10.1016/j.drugalcdep.2014.06.014.
61. Freudenthal, R.I., Martin, J., Wall, M.E., Distribution of Δ9-tetrahydrocannabinol in the mouse. British Journal of Pharmacology 44:2 (1972), 244–249, 10.1111/j.1476-5381.1972.tb07260.x.
62. Fried, P.A., Short and long-term effects of pre-natal Cannabis inhalation upon rat offspring. Psychopharmacology 50:3 (1976), 285–291, 10.1007/BF00426846.
63. Fried, P.A., Marihuana use by pregnant women: Neurobehavioral effects in neonates. Drug and Alcohol Dependence 6:6 (1980), 415–424, 10.1016/0376-8716(80)90023-X.
64. Fried, P.A., The consequences of marijuana use during pregnancy: A review of the human literature. Women and Cannabis: Medicine, Science, and Sociology 2:3 (2002), 85–104.
65. Fried, P.A., Buckingham, M., Von Kulmiz, P., Marijuana use during pregnancy and perinatal risk factors. American Journal of Obstetrics and Gynecology 146:8 (1983), 992–994, 10.1016/0002-9378(83)90989-4.
66. Fried, P.A., James, D.S., Watkinson, B., Growth and pubertal milestones during adolescence in offspring prenatally exposed to cigarettes and marihuana. Neurotoxicology and Teratology 23:5 (2001), 431–436, 10.1016/S0892-0362(01)00161-1.
67. Fried, P.A., O'Connell, C.M., A comparison of the effects of prenatal exposure to tobacco, alcohol, cannabis and caffeine on birth size and subsequent growth. Neurotoxicology and Teratology 9:2 (1987), 79–85, 10.1016/0892-0362(87)90082-1.
68. Fried, P.A., O'Connell, C.M., Watkinson, B., 60- and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: Cognitive and language assessment. Journal of Developmental & Behavioral Pediatrics 13:6 (1992), 383–391.
69. Fried, P.A., Smith, A.M., A literature review of the consequences of prenatal marihuana exposure - An emerging theme of a deficiency in aspects of executive function. Neurotoxicology and Teratology 23:1 (2001), 1–11, 10.1016/S0892-0362(00)00119-7.
70. Fried, P.A., Watkinson, B., 12- and 24-month neurobehavioural follow-up of children prenatally exposed to marihuana, cigarettes and alcohol. Neurotoxicology and Teratology 10:4 (1988), 305–313, 10.1016/0892-0362(88)90032-3.
71. Fried, P.A., Watkinson, B., 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. Journal of Developmental & Behavioral Pediatrics 11:2 (1990), 49–58.
72. Fried, P.A., Watkinson, B., Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicology and Teratology 23:5 (2001), 421–430, 10.1016/S0892-0362(01)00160-X.
73. Fried, P.A., Watkinson, B., Dillon, R.F., Dulberg, C.S., Neonatal neurological status in a low-risk population after prenatal exposure to cigarettes, marijuana, and alcohol. Journal of Developmental & Behavioral Pediatrics 8:6 (1987), 318–326 (https://doi.org/0196-206x/87/0806-0318$02.00/0).
74. Fried, P.A., Watkinson, B., Gray, R., A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes, and alcohol. Neurotoxicology and Teratology 14:5 (1992), 299–311.
75. Fried, P.A., Watkinson, B., Gray, R., Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicology and Teratology 20:3 (1998), 293–306, 10.1016/S0892-0362(97)00091-3.
76. Fried, P.A., Watkinson, B., Gray, R., Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana. Neurotoxicology and Teratology 21:5 (1999), 513–525, 10.1016/S0892-0362(99)00009-4.
77. Fried, P.A., Watkinson, B., Gray, R., Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicology and Teratology 25:4 (2003), 427–436, 10.1016/S0892-0362(03)00029-1.
78. Fried, P.A., Watkinson, B., Siegel, L.S., Reading and language in 9- to 12-year olds prenatally exposed to cigarettes and marijuana. Neurotoxicology and Teratology 19:3 (1997), 171–183, 10.1016/S0892-0362(97)00015-9.
79. Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., Piomelli, D., A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nature Neuroscience 15:1 (2012), 64–69, 10.1038/nn.2986.
80. Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M., Maccarrone, M., Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in Lipid Research 52:4 (2013), 633–650, 10.1016/j.plipres.2013.05.004.
81. Galve-Roperh, I., Palazuelos, J., Aguado, T., Guzmán, M., The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience 259:7 (2009), 371–382, 10.1007/s00406-009-0028-y.
82. Garcia-Gil, L., Romero, J., Ramos, J.A., Fernandez-Ruiz, J.J., Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol. Drug and Alcohol Dependence 55:1–2 (1999), 127–136.
83. Garg, M., Garrison, L., Leeman, L., Hamidovic, A., Borrego, M., Rayburn, W.F., Bakhireva, L., Validity of self-reported drug use information among pregnant women. Maternal and Child Health Journal 20:1 (2016), 41–47, 10.1007/s10995-015-1799-6.
84. Garrett, E.R., Hunt, A.C., Pharmacokinetics of Δ9-tetrahydrocannabinol in dogs. Journal of Pharmaceutical Sciences 66:3 (1977), 395–407, 10.1002/jps.2600660322.
85. Gianutsos, G., Abbatiello, E.R., The effect of pre-natal Cannabis sativa on maze learning ability in the rat. Psychopharmacologia 27:2 (1972), 117–122, 10.1007/BF00439370.
86. Ginsburg, B.C., Hruba, L., Zaki, A., Javors, M.A., McMahon, L.R., Blood levels do not predict behavioral or physiological effects of ∆ 9-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure. Drug and Alcohol Dependence 139 (2014), 1–8, 10.1016/j.drugalcdep.2014.02.696.
87. Glaz-Sandberg, A., Dietz, L., Nguyen, H., Oberwittler, H., Aderjan, R., Mikus, G., Pharmacokinetics of 11-nor-9-carboxy-∆9-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clinical Pharmacology and Therapeutics 82:1 (2007), 63–69, 10.1038/sj.clpt.6100199.
88. Goldschmidt, L., Day, N.L., Richardson, G.A., Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicology and Teratology 22:3 (2000), 325–336, 10.1016/S0892-0362(00)00066-0.
89. Goldschmidt, L., Richardson, G.A., Cornelius, M.D., Day, N.L., Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicology and Teratology 26:4 (2004), 521–532, 10.1016/j.ntt.2004.04.003.
90. Goldschmidt, L., Richardson, G.A., Larkby, C., Day, N.L., Early marijuana initiation: The link between prenatal marijuana exposure, early childhood behavior, and negative adult roles. Neurotoxicology and Teratology 58 (2016), 40–45, 10.1016/j.ntt.2016.05.011.
91. Goldschmidt, L., Richardson, G.A., Willford, J., Day, N.L., Prenatal marijuana exposure and intelligence test performance at age 6. Journal of the American Academy of Child and Adolescent Psychiatry 47:3 (2008), 254–263, 10.1097/CHI.0b013e318160b3f0.
92. Grant, K.S., Rice, D.C., Exposure to environmental chemicals and developmental risk. Burbacher, T.M., Sackett, G.P., Grant, K.S., (eds.) Primate models of children's health and developmental disabilities, 2008, Elsevier, 377–419.
93. Gray, K.A., Day, N.L., Leech, S., Richardson, G.A., Prenatal marijuana exposure: Effect on child depressive symptoms at ten years of age. Neurotoxicology and Teratology 27 (2005), 439–448, 10.1016/j.ntt.2005.03.010.
94. Grotenhermen, F., Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics 42:4 (2003), 327–360, 10.2165/00003088-200342040-00003.
95. Grotenhermen, F., Russo, E., Zuardi, A.W., Even high doses of oral cannabidol do not cause THC-like effects in humans: Comment on Merrick et al. cannabis and cannabinoid research 2016;1(1):102–112; DOI: 10.1089/can.2015.0004. Cannabis and Cannabinoid Research 2:1 (2017), 1–4, 10.1089/can.2016.0036.
96. Harkany, T., Keimpema, E., Barabás, K., Mulder, J., Endocannabinoid functions controlling neuronal specification during brain development. Molecular and Cellular Endocrinology 286:1–2 (2008), S84–S90, 10.1016/j.mce.2008.02.011.
97. Harkany, T., Mackie, K., Doherty, P., Wiring and firing neuronal networks: Endocannabinoids take center stage. Current Opinion in Neurobiology 18:3 (2008), 338–345, 10.1016/j.conb.2008.08.007.
98. Huestis, M.A., Human cannabinoid pharmacokinetics. Chemical Biodiversity 4:8 (2007), 1770–1804, 10.1002/cbdv.200790152.Human.
99. Hunault, C.C., Mensinga, T.T., de Vries, I., Kelholt-Dijkman, H.H., Hoek, J., Kruidenier, M., Meulenbelt, J., Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology 201:2 (2008), 171–181.
100. Hunt, C., Jones, R., Tolerance and disposition of tetrahydrocannabinol in man. Journal of Pharmacology and Experimental Therapeutics 215:1 (1980), 35–44, 10.1017/CBO9781107415324.004.
101. Hurd, Y.L., Wang, X., Anderson, V., Beck, O., Minkoff, H., Dow-Edwards, D., Marijuana impairs growth in mid-gestation fetuses. Neurotoxicology and Teratology 27:2 (2005), 221–229, 10.1016/j.ntt.2004.11.002.
102. Hutchings, D.E., Brake, S.C., Banks, A.N., Nero, T.J., Dick, L.S., Zmitrovich, A.C., Prenatal delta-9-tetrahydrocannabinol in the rat: Effects on auditory startle in adulthood. Neurotoxicology and Teratology 13:4 (1991), 413–416, 10.1016/0892-0362(91)90090-J.
103. Hutchings, D.E., Dow-Edwards, D., Animal models of opiate, cocaine, and cannabis use. Clinics in Perinatology 18:1 (1991), 1–22.
104. Hutchings, D.E., Fico, T.A., Banks, A.N., Dick, L.S., Brake, S.C., Prenatal delta-9-tetrahydrocannabinol in the rat: Effects on postweaning growth. Neurotoxicology and Teratology 13:2 (1991), 245–248, 10.1016/0892-0362(91)90018-R.
105. Hutchings, D.E., Gamagaris, Z., Miller, N., Fico, T.A., The effects of prenatal exposure to delta-9-tetrahydrocannabinol on the rest-activity cycle of the preweanling rat. Neurotoxicology and Teratology 11 (1989), 353–356.
106. Hutchings, D.E., Martin, B.R., Gannagaris, Z., Miller, N., Fico, T., Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple dosing in rats. Life Sciences 44 (1989), 697–701.
107. Hutchings, D.E., Morgan, B., Brake, S.C., Shi, T., Lasalle, E., Delta-9-tetrahydrocannabinol during pregnancy in the rat: I. Differential effects on maternal nutrition, embryotoxicity, and growth in the offspring. Neurotoxicology and Teratology 9:1 (1987), 39–43, 10.1016/0892-0362(87)90068-7.
108. Isoherranen, N., Thummel, K.E., Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes?. Drug Metabolism and Disposition 41:2 (2013), 256–262, 10.1124/dmd.112.050245.
109. Jaddoe, V.W.V., Van Duijn, C.M., Van Der Heijden, A.J., MacKenbach, J.P., Moll, H.A., Steegers, E.A.P., Hofman, A., The Generation R Study: Design and cohort update until the age of 4 years. European Journal of Epidemiology 23:12 (2008), 801–811, 10.1007/s10654-008-9309-4.
110. Jaddoe, V.W.V., Van Duijn, C.M., Van Der Heijden, A.J., MacKenbach, J.P., Moll, H.A., Steegers, E.A.P., Hofman, A., The Generation R Study: Design and cohort update 2010. European Journal of Epidemiology 25:11 (2010), 823–841, 10.1007/s10654-010-9516-7.
111. Karlsson, M., Contreras, J.A., Hellman, U., Tornqvist, H., Holm, C., cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. Journal of Biological Chemistry 272:43 (1997), 27218–27223, 10.1074/jbc.272.43.27218.
112. Katona, I., Freund, T.F., Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nature Medicine 14:9 (2008), 923–930, 10.1038/nm.f.1869.
113. Katona, I., Freund, T.F., Multiple functions of endocannabinoid signaling in the brain. Annual Review of Neuroscience 35:1 (2012), 529–558, 10.1146/annurev-neuro-062111-150420.
114. Kauert, G.F., Ramaekers, J.G., Schneider, E., Moeller, M.R., Toennes, S.W., Pharmacokinetic properties of ∆ 9-tetrahydrocannabinol in serum and oral fluid. Journal of Analytical Toxicology 31 (2007), 288–293, 10.1093/jat/31.5.288.
115. Keimpema, E., Barabás, K., Morozov, Y.M., Tortoriello, G., Torii, M., Cameron, G., Harkany, T., Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. The Journal of Neuroscience 30:42 (2010), 13992–14007, 10.1523/JNEUROSCI.2126-10.2010.
116. Keimpema, E., Mackie, K., Harkany, T., Molecular model of cannabis sensitivity in developing neuronal circuits. Trends in Pharmacological Sciences 32:9 (2011), 551–561, 10.1016/j.tips.2011.05.004.
117. Klausner, H.A., Dingell, J.V., The metabolism and excretion of Δ9-tetrahydrocannabinol in the rat. Life Sciences 10 (1971), 49–59, 10.1016/0024-3205(71)90245-1.
118. Klumpers, L.E., Beumer, T.L., van Hasselt, J.G., Lipplaa, A., Karger, L.B., Kleinloog, H.D., van Gerven, J.M., Novel Δ(9)-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. British Journal of Clinical Pharmacology 74:1 (2012), 42–53.
119. Lapoint, J., James, L.P., Moran, C.L., Nelson, L.S., Hoffman, R.S., Moran, J.H., Severe toxicity following synthetic cannabinoid ingestion. Clinical Toxicology 49:8 (2011), 760–764, 10.3109/15563650.2011.609822.
120. Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., Denovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology 172:20 (2015), 4790–4805, 10.1111/bph.13250.
121. Lee, D., Vandrey, R., Mendu, D.R., Murray, J.A., Barnes, A.J., Huestis, M.A., Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. Drug Testing and Analysis 7:6 (2015), 494–501.
122. Leech, S.L., Larkby, C.A., Day, R., Day, N.L., Predictors and correlates of high levels of depression and anxiety symptoms among children at age 10. Journal of the American Academy of Child and Adolescent Psychiatry 45:2 (2006), 223–230, 10.1097/01.chi.0000184930.18552.4d.
123. Lemberger, L., Axelrod, J., Kopin, I.J., Metabolism and disposition of tetrahydrocannabinols in naive subjects and chronic marijuana users. Annals of the New York Academy of Sciences 191:1 (1971), 142–154, 10.1111/j.1749-6632.1971.tb13994.x.
124. Leuschner, J.T.A., Harvey, D.J., Bullingham, R.E.S., Paton, W.D.M., Pharmacokinetics of delta-9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. Drug Metabolism and Disposition 14:2 (1986), 230–238.
125. Linn, S., Schoenbaum, S.C., Monson, R.R., Rosner, R., Stubblefield, P.C., Ryan, K.J., The association of marijuana use with outcome of pregnancy. Am. J. Public Health 73:10 (1983), 1161–1164 (PMID: 6604464).
126. Lipari, R., International, R, Kroutil, L.A., Pemberton, M.R., Risk and protective factors and initiation of substance use: Results from the 2014 National Survey on Drug Use and Health. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DR-FRR4-2014rev/NSDUH-DR-FRR4-2014.pdf, 2015.
127. López-Gallardo, M., López-Rodríguez, A.B., Llorente-Berzal, Á., Rotllant, D., Mackie, K., Armario, A., Viveros, M.P., Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion. Neuroscience 204 (2012), 90–103, 10.1016/j.neuroscience.2011.09.063.
128. Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., Harkany, T., Programming of neural cells by (endo)cannabinoids: From physiological rules to emerging therapies. Nature Reviews Neuroscience 15:12 (2014), 786–801, 10.1038/nrn3846.
129. Mark, K., Gryczynski, J., Axenfeld, E., Schwartz, R.P., Terplan, M., Pregnant women's current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. Journal of Addiction Medicine 11:3 (2017), 211–216, 10.1097/ADM.0000000000000299 (PMID: 28252456).
130. Marrs, W., Stella, N., 2-AG + 2 new players = forecast for therapeutic advances. Chemistry & Biology 14:12 (2007), 1309–1311, 10.1016/j.chembiol.2007.12.004.
131. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Lutz, B., CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:5642 (2003), 84–88, 10.1126/science.1088208.
132. Marsot, A., Audebert, C., Attolini, L., Lacarelle, B., Micallef, J., Blin, O., Comparison of cannabinoid concentrations in plasma, oral fluid and urine in occasional cannabis smokers after smoking cannabis cigarette. Journal of Pharmacy & Pharmaceutical Sciences, 19(3), 2016, 411, 10.18433/J3F31D.
133. Martin, B.R., Dewey, W.L., Harris, L.S., Beckner, J.S., 3H-∆9-tetrahydrocannabinol distribution in pregnant dogs and their fetuses. Research Communications in Chemical Pathology and Pharmacology 17:3 (1977), 457–470 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/897339.
134. Mathews, C.A., Scharf, J.M., Miller, L.L., Macdonald-Wallis, C., Lawlor, D.A., Ben-Shlomo, Y., Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. British Journal of Psychiatry 204:1 (2014), 40–45, 10.1192/bjp.bp.112.125468.
135. Mazur, A., Lichti, C.F., Prather, P.L., Zielinska, A.K., Bratton, S.M., Gallus-Zawada, A., Moran, J.H., Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metabolism and Disposition: The Biological Fate of Chemicals 37:7 (2009), 1496–1504, 10.1124/dmd.109.026898.
136. Mckinney, M.K., Cravatt, B.F., Structure and function of fatty acid amide hydrolase. Annual Review of Biochemistry 74:1 (2005), 411–432, 10.1146/annurev.biochem.74.082803.133450.
137. McLemore, G.L., Richardson, K.A., Data from three prospective longitudinal human cohorts of prenatal marijuana exposure and offspring outcomes from the fetal period through young adulthood. Data in Brief 9 (2016), 753–757, 10.1016/j.dib.2016.10.005.
138. Mereu, G., Fà, M., Ferraro, L., Cagiano, R., Antonelli, T., Tattoli, M., Cuomo, V., Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proceedings of the National Academy of Sciences of the United States of America 100:8 (2003), 4915–4920, 10.1073/pnas.0537849100.
139. Metna-Laurent, M., Marsicano, G., Rising stars: Modulation of brain functions by astroglial type-1 cannabinoid receptors. Glia 63:3 (2015), 353–364, 10.1002/glia.22773.
140. Miller, A.M., Stella, N., CB2 receptor-mediated migration of immune cells: It can go either way. British Journal of Pharmacology 153:2 (2008), 299–308, 10.1038/sj.bjp.0707523.
141. Moreno, M., Trigo, J.M., Escuredo, L., Rodriguez de Fonseca, F., Navarro, M., Perinatal exposure to ∆ 9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: A behavioral study in rats. Pharmacology Biochemistry and Behavior 75:3 (2003), 565–575, 10.1016/S0091-3057(03)00117-5.
142. Mulder, J., Aguado, T., Keimpema, E., Barabás, K., Ballester Rosado, C.J., Nguyen, L., Harkany, T., Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proceedings of the National Academy of Sciences of the United States of America 105:25 (2008), 8760–8765, 10.1073/pnas.0803545105.
143. Musshoff, F., Madea, B., Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Therapeutic Drug Monitoring 28:2 (2006), 155–163, 10.1097/01.ftd.0000197091.07807.22.
144. Naef, M., Russmann, S., Petersen-Felix, S., Brenneisen, R., Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. Journal of Pharmaceutical Sciences 93:5 (2004), 1176–1184.
145. Narimatsu, S., Matsubara, K., Shimonishi, T., Watanabe, K., Yamamoto, I., Yoshimura, H., Enzymatic oxidation of 7-hydroxylated delta 8-tetrahydrocannabinol to 7-oxo-delta 8-tetrahydrocannabinol by hepatic microsomes of the guinea pig. Drug Metabolism and Disposition: The Biological Fate of Chemicals 16:1 (1988), 156–161.
146. Narimatsu, S., Watanabe, K., Matsunaga, T., Yamamoto, I., Imaoka, S., Funae, Y., Yoshimura, H., Cytochrome P-450 isozymes in metabolic activation of delta 9-tetrahydrocannabinol by rat liver microsomes. Drug Metabolism and Disposition, 18(6), 1990.
147. Narimatsu, S., Watanabe, K., Matsunaga, T., Yamamoto, I., Imaoka, S., Funae, Y., Yoshimura, H., Cytochrome P-450 isozymes involved in the oxidative metabolism of delta 9-tetrahydrocannabinol by liver microsomes of adult female rats. Drug Metabolism and Disposition 20:1 (1992), 79–83.
148. National Academies Press, The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. 2017, National Academies of Sciences Engineering and Medicine, Washington, D.C., 10.17226/24625.
149. Navarrete, M., Araque, A., Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68:1 (2010), 113–126, 10.1016/j.neuron.2010.08.043.
150. Navarro, M., Rubio, P., Rodriguez de Fonseca, F., Behavioral consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology 122:1 (1995), 1–14.
151. Newsom, R.J., Kelly, S.J., Perinatal delta-9-tetrahydrocannabinol exposure disrupts social and open field behavior in adult male rats. Neurotoxicology and Teratology 30:3 (2008), 213–219, 10.1016/j.ntt.2007.12.007.
152. Noland, J.S., Singer, L.T., Short, E.J., Minnes, S., Arendt, R.E., Kirchner, H.L., Bearer, C., Prenatal drug exposure and selective attention in preschoolers. Neurotoxicology and Teratology 27 (2005), 429–438, 10.1016/j.ntt.2005.02.001.
153. Nomura, D.K., Morrison, B.E., Blankman, J.L., Long, J.Z., Kinsey, S.G., Marcondes, M.C.G., Cravatt, B.F., Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334:6057 (2011), 809–813, 10.1126/science.1209200.
154. O'Shea, M., Mallet, P.E., Impaired learning in adulthood following neonatal ∆ 9-THC exposure. Behavioural Pharmacology 16:5–6 (2005), 455–461 (https://doi.org/00008877-200509000-00019 [pii]).
155. Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurell, S., Hollister, L.E., Gillespie, H.K., Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology and Therapeutics 28:3 (1980), 409–416, 10.1038/clpt.1980.181.
156. Oliveira da Cruz, J.F., Robin, L.M., Drago, F., Marsicano, G., Metna-Laurent, M., Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. Neuroscience 323 (2016), 35–42, 10.1016/j.neuroscience.2015.05.002.
157. Parikh, N., Kramer, W.G., Khurana, V., Smith, C.C., Vetticaden, S., Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clinical Pharmacology: Advances and Applications 8 (2016), 155–162.
158. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British Journal of Pharmacology 153:2 (2008), 199–215, 10.1038/sj.bjp.0707442.
159. Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P.H., Di Marzo, V., Elphick, M.R., Ross, R.A., International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacological Reviews 62:4 (2010), 588–631, 10.1124/pr.110.003004.
160. Piomelli, D., The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience 4:11 (2003), 873–884, 10.1038/nrn1247.
161. Renard, J., Norris, C., Rushlow, W., Laviolette, S.R., Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments. Neuroscience & Biobehavioral Reviews 75 (2017), 157–165, 10.1016/j.neubiorev.2017.02.006.
162. Renard, J., Rosen, L.G., Loureiro, M., De Oliveira, C., Schmid, S., Rushlow, W.J., Laviolette, S.R., Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex. Cerebral Cortex 27:2 (2017), 1297–1310, 10.1093/cercor/bhv335.
163. Richardson, G.A., Day, N.L., Goldschmidt, L., Prenatal alcohol, marijuana, and tobacco use: Infant mental and motor development. Neurotoxicology and Teratology 17:4 (1995), 479–487, 10.1016/0892-0362(95)00006-D.
164. Richardson, G.A., Day, N.L., Taylor, P.M., The effect of prenatal alcohol, marijuana, and tobacco exposure on neonatal behavior. Infant Behavior & Development 12:2 (1989), 199–209, 10.1016/0163-6383(89)90006-4.
165. Richardson, G.A., Ryan, C., Willford, J., Day, N.L., Goldschmidt, L., Prenatal alcohol and marijuana exposure: Effects on neuropsychological outcomes at 10 years. Neurotoxicology and Teratology 24:3 (2002), 309–320, 10.1016/S0892-0362(02)00193-9.
166. Rosenthaler, S., Pöhn, B., Kolmanz, C., Nguyen Huu, C., Krewenka, C., Huber, A., Moldzio, R., Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicology and Teratology 46 (2014), 49–56, 10.1016/j.ntt.2014.09.003.
167. Ross, R.A., The enigmatic pharmacology of GPR55. Trends in Pharmacological Sciences 30:3 (2009), 156–163, 10.1016/j.tips.2008.12.004.
168. Rubio, P., Rodríguez de Fonseca, F., Muñoz, R.M., Ariznavarreta, C., Martín-Calderón, J.L., Navarro, M., Long-term behavioral effects of perinatal exposure to delta 9-tetrahydrocannabinol in rats: possible role of pituitary-adrenal axis. Life Sci. 56:23–24 (1995), 2169–2176 (PMID: 7776846).
169. Saurel-Cubizolles, M.J., Prunet, C., Blondel, B., Cannabis use during pregnancy in France in 2010. BJOG: An International Journal of Obstetrics and Gynaecology 121:8 (2014), 971–977, 10.1111/1471-0528.12626.
170. Scher, M.S., Richardson, G.A., Coble, P.A., Day, N.L., Stoffer, D.S., The effects of prenatal alcohol and marijuana exposure: Disturbances in neonatal sleep cycling and arousal. Pediatric Research 24:1 (1988), 101–105.
171. Schwilke, E.W., Schwope, D.M., Karschner, E.L., Lowe, R.H., William, D., Kelly, D.L., Huestis, M.A., ∆ 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clinical Chemistry 55:12 (2009), 2180–2189, 10.1373/clinchem.2008.122119.
172. Sharir, H., Abood, M.E., Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacology and Therapeutics 126:3 (2010), 301–313, 10.1016/j.pharmthera.2010.02.004.
173. Silva, L., Zhao, N., Popp, S., Dow-Edwards, D., Prenatal tetrahydrocannabinol (THC) alters cognitive function and amphetamine response from weaning to adulthood in the rat. Neurotoxicology and Teratology 34:1 (2012), 63–71, 10.1016/j.ntt.2011.10.006.
174. Smith, A.M., Fried, P.A., Hogan, M.J., Cameron, I., Effects of prenatal marijuana on response inhibition: An fMRI study of young adults. Neurotoxicology and Teratology 26:4 (2004), 533–542, 10.1016/j.ntt.2004.04.004.
175. Smith, A.M., Fried, P.A., Hogan, M.J., Cameron, I., Effects of prenatal marijuana on visuospatial working memory: An fMRI study in young adults. Neurotoxicology and Teratology 28:2 (2006), 286–295, 10.1016/j.ntt.2005.12.008.
176. Smith, A.M., Mioduszewski, O., Hatchard, T., Byron-Alhassan, A., Fall, C., Fried, P.A., Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. Neurotoxicology and Teratology 58 (2016), 53–59, 10.1016/j.ntt.2016.05.010.
177. Sonon, K.E., Richardson, G.A., Cornelius, J., Kim, K.H., Day, N.L., Prenatal marijuana exposure predicts marijuana use in young adulthood. Neurotoxicology and Teratology 47 (2015), 10–15, 10.1016/j.ntt.2014.11.003.
178. Stella, N., Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58:9 (2010), 1017–1030, 10.1002/glia.20983.
179. Stella, N., Neuroscience. Inflammation to rebuild a brain. Science 338:6112 (2012), 1303–1304, 10.1126/science.1232331.
180. Stella, N., Piomelli, D., Receptor-dependent formation of endogenous cannabinoids in cortical neurons. European Journal of Pharmacology 425:3 (2001), 189–196, 10.1016/S0014-2999(01)01182-7.
181. Stella, N., Schweitzer, P., Piomelli, D., A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:6644 (1997), 773–778, 10.1038/42015.
182. Stott, C., White, L., Wright, S., Wilbraham, D., Guy, G., A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. SpringerPlus, 2(1), 2013, 236, 10.1186/2193-1801-2-236.
183. Thompson, B.L., Levitt, P., Stanwood, G.D., Prenatal exposure to drugs: Effects on brain development and implications for policy and education. Nature Reviews Neuroscience 10:4 (2009), 303–312, 10.1038/nrn2598.
184. Todd, S.M., Arnold, J.C., Neural correlates of interactions between cannabidiol and Δ(9)-tetrahydrocannabinol in mice: Implications for medical cannabis. British Journal of Pharmacology 173:1 (2016), 53–65, 10.1111/bph.13333.
185. Toennes, S.W., Schneider, K., Kauert, G.F., Wunder, C., Moeller, M.R., Theunissen, E.L., Ramaekers, J.G., Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Analytical and Bioanalytical Chemistry 400:1 (2011), 145–152.
186. Tornqvist, H., Belfrage, P., Purification and some properties of a monoacylglycerol-hydrolyzing enzyme of rat adipose tissue. Journal of Biological Chemistry 251:3 (1976), 813–819.
187. Tortoriello, G., Morris, C.V., Alpár, A., Fuzik, J., Shirran, S.L., Calvigioni, D., Harkany, T., Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. The EMBO Journal 33:7 (2014), 668–685, 10.1002/embj.201386035.
188. Trezza, V., Campolongo, P., Cassano, T., Macheda, T., Dipasquale, P., Carratù, M.R., Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: A longitudinal behavioral study in Wistar rats. Psychopharmacology 198 (2008), 529–537, 10.1007/s00213-008-1162-3.
189. Trezza, V., Campolongo, P., Manduca, A., Morena, M., Palmery, M., Vanderschuren, L.J.M.J., Cuomo, V., Altering endocannabinoid neurotransmission at critical developmental ages: Impact on rodent emotionality and cognitive performance. Frontiers in Behavioral Neuroscience 6 (2012), 1–12, 10.3389/fnbeh.2012.00002.
190. Turner, S.E., Williams, C.M., Iversen, L., Whalley, B.J., Molecular pharmacology of phytocannabinoids. Progress in the Chemistry of Organic Natural Products 103 (2017), 61–101, 10.1007/978-3-319-45541-9_3.
191. van Gelder, M.M.H.J., Reefhuis, J., Caton, A.R., Werler, M.M., Druschel, C.M., Roeleveld, N., Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug and Alcohol Dependence 109:1–3 (2010), 243–247, 10.1016/j.drugalcdep.2010.01.007.
192. Varner, M.W., Silver, R.M., Rowland Hogue, C.J., Willinger, M., Parker, C.B., Thorsten, V.R., Goldenberg, R.L., Saade, G.R., Dudley, D.J., Coustan, D., Stoll, B., Bukowski, R., Koch, M.A., Conway, D., Pinar, H., Reddy, U.M., Eunice Kennedy Shriver National Institute of Child Health and Human Development stillbirth collaborative research network, Association between stillbirth and illicit drug use and smoking during pregnancy. Obstet. Gynecol. 123:1 (2014), 113–125, 10.1097/AOG.0000000000000052.
193. Vitalis, T., Lainé, J., Simon, A., Roland, A., Leterrier, C., Lenkei, Z., The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. European Journal of Neuroscience 28:9 (2008), 1705–1718, 10.1111/j.1460-9568.2008.06484.x.
194. Wall, M.E., Sadler, B.M., Brine, D., Taylor, H., Perez-Reyes, M., Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clinical Pharmacology and Therapeutics 34:3 (1983), 352–363, 10.1038/clpt.1983.179.
195. Warf, B., High points: An historical geography of cannabis. Geographical Review 104:4 (2014), 414–438, 10.1111/j.1931-0846.2014.12038.x.
196. Warner, T.D., Roussos-Ross, D., Behnke, M., It's not your mother's marijuana: Effects on maternal-fetal health and the developing child. Clinics in Perinatology 41:4 (2014), 877–894, 10.1016/j.clp.2014.08.009.
197. Warshak, C., Regan, J., Moore, B., Magner, K., Kritzer, S., Hook, J.V., Association between marijuana use and adverse obstetrical and neonatal outcomes. Journal of Perinatology 35:12 (2015), 991–995, 10.1038/jp.2015.120.
198. Watanabe, K., Yamaori, S., Funahashi, T., Kimura, T., Yamamoto, I., Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sciences 80:15 (2007), 1415–1419, 10.1016/j.lfs.2006.12.032.
199. Westfall, R.E., Janssen, P.A., Lucas, P., Capler, R., Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against “morning sickness”. Complementary Therapies in Clinical Practice 15:4 (2009), 242–246, 10.1016/j.ctcp.2009.07.001.
200. Wise, R.A., Dopamine, learning and motivation. Nature Reviews Neuroscience 5:6 (2004), 483–494, 10.1038/nrn1406.
201. Wu, C.-S., Zhu, J., Wager-Miller, J., Wang, S., O'Leary, D., Monory, K., Lu, H.C., Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. The European Journal of Neuroscience 32:5 (2010), 693–706, 10.1111/j.1460-9568.2010.07337.x.
202. Zammit, S., Thomas, K., Thompson, A., Horwood, J., Menezes, P., Gunnell, D., Harrison, G., Maternal tobacco, cannabis and alcohol use during pregnancy and risk of adolescent psychotic symptoms in offspring. British Journal of Psychiatry 195:4 (2009), 294–300, 10.1192/bjp.bp.108.062471.
203. Zuckerman, B., Amaro, H., Cabral, H., Validity of self-reporting of marijuana and cocaine use among pregnant adolescents. The Journal of Pediatrics, 115, 1989, 10.1016/S0022-3476(89)80668-7.